Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation, Effect on it Own and in Combination With Open Label Nicotine Replacement Therapy.

NCT00738595 is registered in ClinicalTrials.gov with Evotec Neurosciences GmbH as lead sponsor.

NCT NCT00738595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00738595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation, Effect on it Own and in Combination With Open Label Nicotine Replacement Therapy.
Lead sponsor
Evotec Neurosciences GmbH
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
May 31, 2009
Enrollment
400 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation